Shuttle Pharmaceuticals News

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 2 00:28

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 29 21:03

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 29 04:11

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024

Oct 28 21:04

Shuttle Pharmaceuticals | 8-K: Securities Purchase Agreement

Oct 25 20:57

Shuttle Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Oct 18 21:09

Shuttle Pharmaceuticals | 8-K: Securities Purchase Agreement

Oct 18 05:21

Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Sep 20 18:07

Shuttle Pharmaceuticals | 8-K: Current report

Sep 14 05:02

Shuttle Pharmaceuticals | 8-K: Form of Promissory Note, dated September 4, 2024, between Shuttle Pharmaceuticals and Anatoly Dritschilo

Sep 11 05:24

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Sep 5 04:41

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 28 21:03

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 27 04:12

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Ready to Enroll patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Aug 15 04:21

Shuttle Pharmaceuticals | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Aug 13 18:15

Shuttle Pharmaceuticals | 8-K: Certificate of Amendment to Amended and Restated Certificate of Incorporation of Shuttle Pharmaceuticals Holdings, Inc.

Aug 7 20:01

Shuttle Pharmaceuticals | 8-K: Poll Results of 2024 Stockholders Meeting

Aug 1 21:51

Shuttle Pharmaceuticals | 8-K: Current report

Jul 17 05:03

Shuttle Pharmaceuticals | DEF 14A: Definitive information statements

Jun 21 04:02

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory

Jun 18 21:03